SCHEMBL188365

SCHEMBL188365

O=C1C=CC(=O)C(=S)C1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11666359 0.71
SCHEMBL127160 0.67
SCHEMBL2585204 0.67
SCHEMBL366153 0.65 GSK3A (0.71)
Methane SCHEMBL23038597 0.65 GSK3A (0.50)
SCHEMBL10465266 0.65
Formaldehyde SCHEMBL28980261 0.65 GSK3A (0.50)
SCHEMBL4586121 0.62 GSK3A (0.46)
SCHEMBL11698307 0.62 GSK3A (0.46)
SCHEMBL7268889 0.62 GSK3A (0.46)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 283 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3027776-B1 METHODS AND MOLECULAR PHARMACODYNAMIC BIOMARKERS FOR MULTIPLE SIGNALING PATHWAYS IN RESPONSE TO CARBOXYAMIDOTRIAZOLE OROTATE TACTICAL THERAPEUTICS INC (US) 2024-02-07 EP claimed
US-10378059-B2 Methods and molecular pharmacodynamic biomarkers for multiple signaling pathways in response to carboxyamidotriazole orotate TACTICAL THERAPEUTICS, INC. (US) 2019-08-13 US claimed
US-20240058335-A1 METHODS FOR TREATMENT OF CANCER USING ABL INHIBITORS AND DRUGS TARGETING THE MEVALONATE PATHWAY DUKE UNIVERSITY (US) 2024-02-22 US disclosed
US-20240060132-A1 DIAGNOSIS OF SEPSIS BECTON DICKINSON CO (US) 2024-02-22 US disclosed
EP-3027776-B1 METHODS AND MOLECULAR PHARMACODYNAMIC BIOMARKERS FOR MULTIPLE SIGNALING PATHWAYS IN RESPONSE TO CARBOXYAMIDOTRIAZOLE OROTATE TACTICAL THERAPEUTICS INC (US) 2024-02-07 EP disclosed
US-20230383318-A1 METHODS AND SYSTEMS FOR CHEMOAUTOTROPHIC PRODUCTION OF ORGANIC COMPOUNDS GINKGO BIOWORKS, INC. (US) 2023-11-30 US disclosed
US-20230374595-A1 GENE EXPRESSION PROFILES ASSOCIATED WITH CHRONIC ALLOGRAFT NEPHROPATHY THE SCRIPPS RESEARCH INSTITUTE 2023-11-23 US disclosed
US-11821037-B2 Gene expression profiles associated with chronic allograft nephropathy THE SCRIPPS RESEARCH INSTITUTE (US) 2023-11-21 US disclosed
EP-3198007-B1 METHODS AND COMPOSITIONS FOR MODULATING TH-GM CELL FUNCTION NAT UNIV SINGAPORE (SG) 2023-11-01 EP disclosed
US-20230323464-A1 METHOD FOR PREDICTING PROGNOSIS OF PATIENTS HAVING EARLY BREAST CANCER SEOUL NATIONAL UNIVERSITY R&DB FOUNDATION (KR) 2023-10-12 US disclosed
US-11697829-B2 Chemoautotrophic cells comprising an engineered carbon fixation pathway GINKGO BIOWORKS, INC. (US) 2023-07-11 US disclosed
US-7056418-B2 Cooking method for pulp KAWASAKI KASEI CHEMICALS LTD. (JP) 2006-06-06 US disclosed
US-20060056948-A1 Methods AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) 2006-03-16 US disclosed
US-20060046259-A1 Differential expression of molecules associated with acute stroke THE GOV. OF THE U.S.A AS REPRESENTED BY THE SECRETARY OF THE DEPT. OF HEALTH & HUMAN SERVICES 2006-03-02 US disclosed
US-20060019890-A1 Method for treating cardiac remodeling following myocardial injury SCIOIS INC. 2006-01-26 US disclosed
WO-2005116268-A2 DIFFERENTIAL EXPRESSION OF MOLECULES ASSOCIATED WITH ACUTE STROKE THE GOVERNMENT OF THE UNITED STATES OF AMERICA AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH (US) 2005-12-08 WO disclosed
WO-2005070446-A1 METHOD FOR TREATING CARDIAC REMODELING FOLLOWING MYOCARDIAL INJURY SCIOS INC. (US) 2005-08-04 WO disclosed
WO-2005003766-A2 METHODS OF REGULATING METABOLISM AND MITOCHONDRIAL FUNCTION WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) 2005-01-13 WO disclosed
EP-1245721-A1 DIGESTION METHOD FOR PULP Kawasaki Kasei Chemicals Ltd. (JP) 2002-10-02 EP disclosed
US-20020088576-A1 Cooking method for pulp KAWASAKI KASEI CHEMICALS LTD. (JP) 2002-07-11 US disclosed